Overview

Technology That Permits Focal Dose of Antibiotics to be Delivered to Lower Limb(s) of Diabetic Patients

Status:
Completed
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
The use of the Percutaneous Isolated Limb Procedure (PILP) which enables the use of existing antibiotic therapies in a more targeted and concentrated fashion in patients with diabetes who have a significant lower limb infection and it is deemed that IV antibiotics are needed in order to salvage the limb or life.
Phase:
Phase 2
Details
Lead Sponsor:
Osprey Medical, Inc
Treatments:
Anti-Bacterial Agents
Antibiotics, Antitubercular
Clavulanic Acid
Clavulanic Acids
Ticarcillin
Ticarcillin-clavulanic acid